REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

Title
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors
Authors
Keywords
Phase I clinical trial, Reolysin®, Oncolyic virus, Reovirus neutralizing antibody, Dose limiting toxicity (DLT), Maximum tolerated dose (MTD)
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 3, Pages 696-706
Publisher
Springer Nature
Online
2012-08-11
DOI
10.1007/s10637-012-9865-z

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search